Dermorphin: ultra-potent natural opioid from tree-frog skin
A naturally occurring painkiller found in South American tree-frog skin that activates the same brain receptors as morphine, but far more powerfully; banned in sport and has no approved medical use.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Dermorphin is a seven-residue peptide discovered in the skin of the South American tree frog Phyllomedusa sauvagei. It is one of the most potent naturally occurring opioid compounds known — working on the same mu-opioid receptor targeted by morphine, but with far greater potency. It has no approved medical use in any country and is classified as a prohibited substance in sport. The stored sequence YDAFGYPS uses standard letters, but the active peptide carries two hidden modifications: the alanine at position 2 is actually a D-amino acid (D-Ala²), and the C-terminus ends in an amide (-NH₂) rather than a free acid — neither feature is visible in the raw sequence.
History
Dermorphin was isolated and structurally characterized in 1981 by Montecucchi and colleagues working with Phyllomedusa sauvagei skin extracts (Montecucchi et al. 1981). The sequence they reported — Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂ — was striking for two reasons: its extreme opioid potency, documented in the same year by Broccardo and colleagues in isolated organ pharmacology (Broccardo et al. 1981), and the presence of a D-alanine residue at position 2. D-amino acids in vertebrate peptides were considered exceptional at the time, and dermorphin was one of the first confirmed vertebrate examples.
The origin of that D-Ala was clarified in 1987 when Richter and colleagues demonstrated, using cDNA library screening of frog skin mRNA, that the dermorphin precursor protein encodes a standard L-alanine at position 2 — the D-form arises through a post-translational isomerization step, not from a dedicated D-amino acid synthetase (Richter et al. 1987). This was a significant finding for the biology of D-amino acid incorporation in vertebrates.
Dermorphin was never developed as a pharmaceutical. Its extreme potency, respiratory depression risk at high doses, and the general difficulties of bringing a potent opioid through modern clinical development kept it in the research-tool category. The peptide gained broader public attention in the early 2010s when it appeared as an illegal doping agent in horse racing: because early routine opioid screens did not detect it, dermorphin was used illicitly in racehorses before specialized LC-MS/MS assays were developed to identify it in equine plasma and urine (Guan et al. 2013).
What it does
Dermorphin activates mu-opioid receptors — the same receptors that mediate the pain-relieving and euphoric effects of morphine and related opioids. In pharmacological assays conducted at the time of its discovery, it was 39 times more potent than morphine and 57 times more potent than Met-enkephalin in guinea-pig ileum preparations (Broccardo et al. 1981). The primary effects are those expected of a potent mu-opioid agonist: analgesia, sedation, and at high doses respiratory depression.
The D-Ala at position 2 does two things: it makes the peptide resistant to the aminopeptidases that would rapidly degrade a standard L-amino acid peptide, and it is essential for high-affinity binding to the mu-opioid receptor. The C-terminal amide similarly protects against carboxypeptidase attack. Together these modifications give dermorphin a longer duration of action than structurally similar all-L-amino acid opioid peptides.
Research into dermorphin analogs — shorter tetrapeptide variants and chemically modified derivatives — has continued with the aim of separating the analgesic activity from the side-effect profile of the parent compound (Mizoguchi et al. 2011).
Evidence
- Human: Very limited. A single small randomized controlled trial of intrathecal dermorphin in postoperative pain was published in 1985; no further clinical trials have been registered or published in the four decades since.
- Animal: Extensive preclinical pharmacology over several decades, using hot plate, tail-flick, and other pain models in rodents. Potency relative to morphine has been repeatedly characterized across routes of administration and preparations (Broccardo et al. 1981).
- In vitro: Radioligand binding studies in rat brain membranes and isolated organ preparations have characterized dermorphin's mu-receptor selectivity and binding kinetics (Broccardo et al. 1981; Mizoguchi et al. 2011).
Known effects
- Antinociception (pain relief) — Preclinical (extensive animal pharmacology; single 1985 human intrathecal trial)
- Mu-opioid receptor agonism — Mechanistic (well-characterized in binding and organ pharmacology studies)
- Sedation / respiratory depression at high doses — Preclinical (dose-dependent in animal models)
- Proteolytic stability — Mechanistic (D-Ala² and C-terminal amide confer resistance to peptidase degradation)
Safety signals
Dermorphin is a full mu-opioid receptor agonist and carries the class-level risks of potent opioids: respiratory depression, sedation, nausea, and the potential for dependence with repeated use. Animal pharmacology at high doses documents respiratory depression as a dose-dependent effect (Broccardo et al. 1981). The single available human clinical experience — one intrathecal trial from 1985 — was conducted under anesthesiological monitoring; no systematic human safety data exist from systemic routes of administration. Long-term safety, abuse liability in humans, and organ-specific toxicity have not been characterized in clinical studies.
The peptide's potency is itself a safety hazard: because it is far more potent than morphine by weight, small errors in quantity translate to proportionally larger pharmacological effects.
Regulatory status
- US: Not FDA-approved for any indication. Not currently listed by name as a federally scheduled controlled substance, but its pharmacological profile as a potent mu-opioid agonist exposes it to analogue-act enforcement.
- EU / International: Not approved by EMA or any other major regulatory authority. Scheduling under opioid analogue provisions varies by jurisdiction.
- Sport: Prohibited under WADA's narcotics classification (S7) as an opioid agonist used for pain masking. Classified as a Class I prohibited substance by the Association of Racing Commissioners International for equine sport; its detection in racehorses has resulted in sanctions in multiple US racing jurisdictions (Guan et al. 2013).
Mechanism
Dermorphin binds with high selectivity to the mu-opioid receptor (MOR). The N-terminal tetrapeptide — Tyr-D-Ala-Phe-Gly — constitutes the pharmacophore required for opioid receptor recognition, while the C-terminal tripeptide Tyr-Pro-Ser-NH₂ contributes to mu-receptor selectivity. MOR activation inhibits adenylyl cyclase, reducing intracellular cAMP, and modulates ion channel conductance in nociceptive neurons, collectively suppressing pain transmission.
The D-alanine at position 2 is not merely a stability feature — it is required for high-affinity mu binding. The biosynthetic origin of this D-residue (post-translational isomerization from L-Ala, as established by Richter et al. 1987) makes dermorphin a model example of how frog skin peptides achieve pharmacological properties not achievable with standard L-amino acid sequences.
Myths and misconceptions
- "Dermorphin is safer than morphine because animal studies show less tolerance" — Some animal pharmacology data suggests a more favorable tolerance and respiratory profile at equianalgesic doses compared to morphine. These observations have never been validated in modern human clinical trials, and dermorphin remains a full mu-opioid agonist with the class-level risks that entails.
- "As a natural frog-skin peptide, it is a safer alternative to synthetic opioids" — Natural origin is not a safety property. Dermorphin's mechanism is full mu-opioid receptor agonism — pharmacologically equivalent to morphine in kind, and more potent by weight.
- "Dermorphin is undetectable in drug testing" — This was historically true for routine opioid screens. LC-MS/MS methods validated for both equine and human matrices can now detect dermorphin at low concentrations and have been used in anti-doping enforcement since the early 2010s (Guan et al. 2013).
Open questions
- No modern human clinical trials have been conducted in any pain indication; the pharmacological gap between the extensive animal literature and clinical use remains unbridged.
- Systemic (intravenous, subcutaneous) human pharmacokinetics have not been characterized.
- Comparative efficacy versus current standard-of-care analgesics has not been evaluated in a modern clinical setting.
- The interaction profile with other medications is essentially uncharacterized in humans.
Related peptides
- Deltorphins — related family of D-amino acid-containing opioid peptides also isolated from Phyllomedusa species, but with high selectivity for delta- rather than mu-opioid receptors.
- Tetrapeptide dermorphin analogs — shortened Tyr-D-Ala-Phe-Gly derivatives explored as research tools with modified pharmacological profiles distinct from the parent heptapeptide (Mizoguchi et al. 2011).
- Leu-enkephalin and Met-enkephalin — endogenous opioid pentapeptides against which dermorphin's potency was benchmarked in original pharmacology studies; dermorphin is structurally related in its N-terminal Tyr-X-Phe motif but far more potent and proteolytically stable (Broccardo et al. 1981).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could adding a single methyl group to glycine at position 4 of dermorphin block the enzyme scissors that normally cut and destroy it, without disrupting its exceptional grip on the opioid receptor?
If this stabilization works, it would create a research-grade tool for studying pain pathways that lasts long enough to be practically useful in animal studies, an important step toward understanding whether dermorphin's unusual opioid pharmacology can be translated into safer pain medicines.
Does the small chemical modification at the very end of dermorphin allow it to grip a part of the opioid receptor that regular opioid peptides cannot reach?
Knowing exactly why dermorphin is so potent could allow researchers to engineer safer, ultra-low-dose pain medicines that exploit this same grip while avoiding the full set of risks that come with the natural frog peptide.
Do two tyrosine amino acids in dermorphin act as a matched pair that fits specifically into the mu-opioid receptor but not into the closely related delta or kappa opioid receptors?
If this dual-tyrosine lock-and-key mechanism is real, it could guide the design of highly specific pain medicines that activate only the mu-opioid receptor, potentially reducing side effects like sedation and respiratory depression associated with activating multiple opioid receptor types.
Does the unusual mirror-image building block in dermorphin stop the opioid receptor from triggering the molecular cascade that causes the body to adapt and require ever-higher doses?
If confirmed, this would show that one structural trick from a tree frog could guide the design of powerful painkillers that work long-term without requiring dose escalation, directly addressing a core driver of the opioid addiction crisis.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8834590911865234 | boltz-2 |
| ranking score | 0.8037094473838806 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.052 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10694,
sequence = {YDAFGYPS},
target = {oprm1},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}